Supplemental Figure 1 from TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer
Year: 2023
Type: supplementary-materials
Abstract: 1. Supplemental Data: Differential of Toxicity and Eligibility Critique.; 2. Supplemental Figure 1: Gene Expression in Patients With Response to Therapy.
Authors: Andres Forero-Torres, Katherine E. Varley, Vandana G. Abramson, Yufeng Li, Christos Vaklavas, Nancy U. Lin, Minetta C. Liu, Hope S. Rugo, Rita Nanda, Anna M. Storniolo, Tiffany A. Traina, Sujata Patil, Catherine H. Van Poznak, Julie R. Nangia, William J. Irvin, Helen Krontiras, Jennifer F. De Los Santos, Paul Haluska, William Grizzle, Richard M. Myers, Antonio C. Wolff
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4361969957